CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that the Company plans to initiate a Phase III clinical trial of ALTU-135 in Cystic Fibrosis patients with pancreatic insufficiency in the second quarter of 2007.
